| Name | Title | Contact Details |
|---|
Global Technical Talent is a Portsmouth, NH-based company in the Business Services sector.
Willamette Print & Blueprint is a Portland, OR-based company in the Business Services sector.
SMX is a global technology and engineering provider that specializes in digital transformation and mission-critical solutions. Formed in 2021 through the consolidation of several legacy companies, SMX has a history dating back to 1995. The company focuses on delivering secure and scalable solutions to both government and commercial clients, emphasizing innovation and mission acceleration. SMX offers a range of services across six primary domains, including secure cloud solutions, cybersecurity, data and analytics, digital transformation, mission operations and intelligence, and modeling, simulation, and training. Their key products include the SMX Elevate framework, which features generative AI labs, an intelligent automation platform, and managed services for next-gen IT operations. SMX primarily serves the U.S. Department of Defense, federal agencies, and commercial enterprises, ensuring compliance and security in their digital transformation efforts. With a workforce of 1,000 to 5,000 professionals, SMX operates globally with key locations in the DC Metro Area, Alabama, California, and Hawaii.
Lawrence D. Brudy & Associates, Inc. is a Wexford, PA-based company in the Business Services sector.
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos` lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.